JUBLPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.3
| Stock Code | JUBLPHARMA | Market Cap | 14,835 Cr. | Current Price | 931 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.54 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 905 ₹ | DMA 200 | 980 ₹ | Chg in FII Hold | -0.06 % |
| Chg in DII Hold | 0.40 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 60.8 |
| MACD | 19.0 | Volume | 65,033 | Avg Vol 1Wk | 1,21,332 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 31.7 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 30.2 |
📊 Jubilant Pharmova (JUBLPHARMA) shows weak fundamentals but some technical potential for swing trading. The RSI at 60.8 indicates strong momentum, while the MACD (19.0) is positive, reflecting bullish signals. The current price (₹931) is above the 50 DMA (₹905) but below the 200 DMA (₹980), showing short-term strength but medium-term weakness. Fundamentals are poor with ROCE (2.91%) and ROE (1.04%), while EPS is very low (₹1.23). PAT improved sequentially (₹-48 Cr. → ₹6.6 Cr.), but overall profitability remains weak. Debt-to-equity (0.02) is low, providing financial stability, yet valuations are unclear due to missing P/E and PEG ratios.
💡 Optimal Entry Price: Around ₹910–₹930, near 50 DMA support.
📈 Exit Strategy (if already holding): Consider booking profits near ₹960–₹980, close to 200 DMA resistance.
✅ Positive
- Price trading above 50 DMA shows short-term strength.
- MACD positive (19.0) indicates bullish momentum.
- Sequential PAT recovery from a loss (₹-48 Cr.) to profit (₹6.6 Cr.).
- DII holdings increased (+0.40%), showing domestic investor support.
- Low debt-to-equity ratio (0.02) ensures financial stability.
⚠️ Limitation
- Weak ROCE (2.91%) and ROE (1.04%) highlight poor efficiency.
- EPS of ₹1.23 is very low compared to peers.
- P/E ratio not available, making valuation assessment difficult.
- Trading volume below weekly average, indicating reduced activity.
📉 Company Negative News
- Quarterly profit variation shows -13.9% YoY decline.
- Stock trading far below 52-week high (₹1,250), reflecting weak sentiment.
- FII holdings decreased (-0.06%), showing reduced foreign investor confidence.
📈 Company Positive News
- Sequential PAT recovery from losses to profit.
- EPS positive despite weak margins.
- DII holdings increased (+0.40%), signaling domestic support.
🏭 Industry
- Industry PE at 30.2 vs. missing company P/E makes comparison difficult.
- Pharmaceutical sector benefits from long-term demand but faces margin pressures.
🔎 Conclusion
JUBLPHARMA is technically showing short-term strength but fundamentally weak with poor efficiency and low earnings. Swing traders may cautiously enter near ₹910–₹930, targeting exits around ₹960–₹980. Risk management is essential given weak profitability and uncertain valuations.